BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a partial sequence of human gastric juice protein. It has been extensively studied in preclinical models for its effects on tissue repair mechanisms, angiogenesis, and cytoprotective signaling pathways.

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a sequence found in human gastric juice. It is one of the most studied peptides in preclinical research, with published investigations spanning tissue repair, cytoprotection, and angiogenesis. Supplied as a lyophilized research peptide for laboratory use.

BPC-157 was first isolated and characterized by researchers led by Predrag Sikiric at the University of Zagreb, Croatia, beginning in the early 1990s. The peptide sequence was derived from a stable gastric pentadecapeptide found in human gastric juice. Since its initial characterization, over 100 published preclinical studies have examined its biological activity across multiple tissue systems.

Preclinical studies have demonstrated that BPC-157 modulates nitric oxide (NO) pathways, promotes angiogenesis via VEGF upregulation, and influences growth factor expression in wound healing models. Research in animal models has shown activity in musculoskeletal, gastrointestinal, and neurological tissue repair assays. Its mechanism of action appears to involve multiple signaling cascades including the FAK-paxillin and JAK-2/STAT-3 pathways.